Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use

被引:21
作者
Wiegratz, Inka [1 ]
Stahlberg, Skadi [1 ]
Manthey, Torsten [1 ]
Saenger, Nicole [1 ]
Mittmann, Katrin [2 ]
Palombo-Kinne, Ernesta [2 ]
Mellinger, Uwe [2 ]
Lange, Evelyn [2 ]
Kuhl, Herbert [1 ]
机构
[1] Univ Hosp Frankfurt, Ctr Obstet & Gynecol, D-60590 Frankfurt, Germany
[2] Jenapharm GmbH & Co KG, D-07745 Jena, Germany
关键词
Oral contraceptives; Extended-cycle regimen; Ethinyl estradiol; Dienogest; Lipid metabolism; MYOCARDIAL-INFARCTION; MU-G; CARBOHYDRATE-METABOLISM; DESOGESTREL; LIPOPROTEIN; GESTODENE; RISK; ETHINYLESTRADIOL; LEVONORGESTREL; DROSPIRENONE;
D O I
10.1016/j.contraception.2009.07.011
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: The effects of extended regimens of combined oral contraceptives (COC) on lipid parameters are largely unknown. The present study compared the effects of a COC containing 30 mcg ethinyl estradiol and 2 mg dienogest (EE/DNG) in conventional and extended-cycle regimen over 1 year. Study Design: Lipid parameters were measured in 59 women treated with EE/DNG either conventionally (21+7 days) or in extended-cycle regimen (84+7 days). Blood samples were taken in a control cycle and at 3 and 12 months of treatment. Results: The mean levels of total cholesterol, HDL cholesterol and HDL2 cholesterol underwent modest to moderate significant increases over time, while the significant increase in triglycerides and VLDL cholesterol was more pronounced with both regimens. LDL cholesterol decreased slightly in both regimen groups, whereas lipoprotein(a) was transiently decreased at 3 months only in the extended-cycle group. The changes reached a steady-state at latest at 3 months, but did not exceed the given normal ranges for any of the parameters. Notably, except for lipoprotein(a), the changes in mean lipid levels were not significantly different in the conventional and the extended-cycle regimen at 3 or 12 months of treatment. Conclusion: Use of EE/DNG in conventional or extended-cycle regimen resulted in comparable changes of lipid parameters. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 25 条
[11]   CHANGES IN LIPID-METABOLISM DURING 12 MONTHS OF TREATMENT WITH 2 ORAL-CONTRACEPTIVES CONTAINING 30-MU-G ETHINYLESTRADIOL AND 75-MU-G GESTODENE OR 150-MU-G DESOGESTREL [J].
MARZ, W ;
JUNGHOFFMANN, C ;
HEIDT, F ;
GROSS, W ;
KUHL, H .
CONTRACEPTION, 1990, 41 (03) :245-258
[12]   EFFECTS OF A NEW ORAL-CONTRACEPTIVE CONTAINING ARM ANTIMINERALOCORTICOID PROGESTOGEN, DROSPIRENONE, ON THE RENIN-ALDOSTERONE SYSTEM, BODY-WEIGHT, BLOOD-PRESSURE, GLUCOSE-TOLERANCE, AND LIPID-METABOLISM [J].
OELKERS, W ;
FOIDART, JM ;
DOMBROVICZ, N ;
WELTER, A ;
HEITHECKER, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (06) :1816-1821
[13]  
PETERSEN KR, 1991, OBSTET GYNECOL, V78, P666
[14]   Oral contraceptive use and myocardial infarction [J].
Petitti, DB ;
Sidney, S ;
Quesenberry, CP .
CONTRACEPTION, 1998, 57 (03) :143-155
[15]   A CROSS-OVER STUDY OF 3 ORAL-CONTRACEPTIVES CONTAINING ETHINYLESTRADIOL AND EITHER DESOGESTREL OR LEVONORGESTREL [J].
SONG, S ;
CHEN, JK ;
YANG, PJ ;
HE, ML ;
LI, LM ;
FAN, BC ;
REKERS, H ;
FOTHERBY, K .
CONTRACEPTION, 1992, 45 (06) :523-532
[16]   Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms [J].
Sulak, PJ ;
Kuehl, TJ ;
Ortiz, M ;
Shull, BL .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (06) :1142-1149
[17]   Oral contraceptives and the risk of myocardial infarction. [J].
Tanis, BC ;
van den Bosch, MAAJ ;
Kemmeren, JM ;
Cats, VM ;
Helmerhorst, FM ;
Algra, A ;
van der Graaf, Y ;
Rosendaal, FR .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1787-1793
[18]   A comparative study of the effects of gestodene 60 μg/ethinylestradiol 15 μg and desogestrel 15μg/ethinylestradiol 20 μg on hemostatic balance, blood lipid levels and carbohydrate metabolism [J].
van der Mooen, M. J. ;
Klipping, C. ;
van Aken, B. ;
Helmerhorst, F. M. ;
Spielmann, D. ;
Kluft, C. .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 1999, 4 :27-35
[19]   Long-cycle treatment with oral contraceptives [J].
Wiegratz, I ;
Kuhl, H .
DRUGS, 2004, 64 (21) :2447-2462
[20]   Progestogen therapies: differences in clinical effects? [J].
Wiegratz, I ;
Kuhl, H .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (06) :277-285